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Objectives: We sought to prospectively compare the prognostic value of
cardiac iodine-123 (I-123) metaiodobenzylguanidine (MIBG) imaging with
peak oxygen comsumption (VO2) and plasma BNP level in patients with
advanced heart failure (AHF) waiting for heart transplant.
Bakground: In mild to moderate heart failure, cardiac fixation of MIBG
reflecting presynaptic uptake is reduced, exercise capacity is altered and
plasma BNP level is increased. In AHF prognostic value of these parameters
is still unknown.
Methods: Fifty one patients with advanced heart failure were studied with
planar MIBG imaging, cardiopulmonary exercise tests, hemodynamic and neu-
rohormonal parameters. Early (30 min) and late (4 h) MIBG acquisition, as
well as their ratio (washout rate, WOR) were determined. Prognostic value
was assessed by survival curves (Kaplan-Meier method) and uni- and multi-
variate Cox analyses.
Results: Early and late cardiac MIBG uptake were correlated with ejec-
tion fraction (r=0.33 and r=0.42). With a median follow up of 494 days,
NYHA (p=0.03), plasma BNP (p=0.002), peak VO2 (p=0.03) were predic-
tive of death or heart transplantation, but only plasma BNP emerged by mul-
tivariate analysis. WOR>36.63% (1st quartile) was predictive on kaplan-
Meier analysis.
Conclusions: In AHF patients, VO2 and BNP plasma level are stronger
prognosticator than MIBG imaging related parameters. MIBG should be
reserved to patients with mild to moderate heart failure while BNP remains the
most powerful prognostic index whatever the severity of heart failure.
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pathetic neural recording
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Background: Levosimendan is a new inodilatory agent with calcium sen-
sitizing activity. A major concern regarding the use of inotropic agent in heart
failure is their effect on the sympathetic tone. This effect could explain
increase in short term mortality with other inotropes. In this setting, the aim of
our study was to assess the effect of levosimendan on sympathetic tone mea-
sured directly by microneurography.
Methods: In a group of acute decompensated heart failure patients, we
assessed cardiac performance by digital plethysmography (Finometer©) mea-
surement. Sympathetic tone was assessed through recording of muscle sympa-
thetic nerve activity by microneurography. Recording were done blindy, for
each patient after dobutamine perfusion was stopped (baseline) and 48 hours
after levosimendan infusion. Clinical, biological and morphological data were
collected. We compared cardiac parameters and sympathetic nerve activity
before and after administration of levosimedan.
Results: 13 patients with refractory chronic heart failure were recruited
(aged 48±3.6 years). Systolic blood pressure and rate pressure product
(mmHg x Beat/min) decreased significantly after levosimendan infusion
(p<0.05). Cardiac output and stroke volume assessed by Finometer were
significantly increased after levosimendan infusion (p<0.05). A significant
decrease of muscle sympathetic nerve activity is observed after levosim-
endan infusion (p<0.01). Levosimendan cause a significant reduction of
plasma brain natriuretic preptide (BNP) after the initiation of the drug
(p<0.01).
Conclusion: Levosimendan induced improvement of cardiac performance
is associated with a decreased in MSNA. This study show for the first time
that levosimendan has no direct detrimental effect on the sympathetic nervous
system.
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Significance of increased plasma BNP level in Patients with Hypertro-
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Background: Plasma BNP is widely used in the management of patients
with systolic heart failure; however it has been less studied in patients with
hypertrophic cardiomyopathy. We hypothetized that increased plasma BNP
level could be associated with heart failure symptoms and increased left ven-
tricle filling pressure in patients with HCM.
Methods: We studied 62 consecutive patients with HCM admitted for
evaluation in our outpatient clinic. In all patients, clinical examination, com-
plete echocardiography and plasma BNP and creatinine measurements were
performed. 
Results: The mean BNP value was 297 ± 282 pg/mL. In univariate anal-
ysis, BNP showed a significant relationship to age (R_ = 0,1862; p = 5.10-
4), magnitude of dyspnea, expressed by New York Heart Association
(NYHA) functional class: I, 114 ± 114 pg/mL; II, 224 ± 168 pg/mL; III,
523 ± 280 pg/mL; IV, 816 ± 368 pg/mL (p < 10-4), atrial fibrillation (p <
0,009) and creatinine clearance (R_ = 0,2328; p < 10-4). BNP levels were
also correlated with lateral annular Ea velocity (R_ = 0,2148; p = 10-4),
increased LV filling pressure defined as E/A > 2 or E/Ea > 10 (R_ = 0,376;
p < 10-4), left atrial size (R_ = 0,1686; p = 9.10-4), systolic pulmonary
arterial pressure (R_ = 0,2299; p < 10-4). There was no relation between
BNP and LV outflow tract gradient at rest or maximal LV wall thickness.
Variables with significant multivariable relation with BNP were NYHA
functional class, mitral lateral Ea velocity, increased LV filling pressure,
and creatinine clearance.
Conclusion: BNP levels in patients with HCM are related to the presence
and magnitude of heart failure symptoms and LV filling pressure. Its prog-
nostic value should be evaluated in these patients. 
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Introduction: In healthy subject hyperoxia enhances metaboreflex sensi-
tivity during static exercise. However the influence of chronic heart failure on
metaboreflex sensibility remains a matter of controversies. Moreover the effect
of hyperoxia on this reflex in CHF patients is unknown. This is of importance
since these patients regularly receive chronic administration of nasal oxygen
during hospital admission.
Methods: The effects of breathing 21% (normoxia) and 100% oxygen
(hyperoxia) at rest and during isometric handgrip at 30% of maximal voluntary
contraction on MSNA, heart rate (HR), blood pressure (systolic, diastolic,
mean and pulse pressure) and O2 saturation (DaO2) were determined in 14
patients with heart failure. The isometric handgrips were followed by 3 min of
post-exercise circulation arrest (PE-CA) to allow metaboreflex activation in
the absence of other reflex mechanisms.
Results: In normoxia, hangrip and PE-CA induced an expected increase in
MSNA and hemodynamic parameters (BP, HR ; all p<0,05). Hyperoxia
enhanced resting diastolic, mean blood pressure and SaO2 (all p<0,05), but
without effects on MSNA responses. Hyperoxia did not modifiy expected
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response of sympathetic and hemodynamic parameters during exercice (all
p<0,05) but response after PE-CA was blunted.
Conclusion: In patients with chronic heart failure, hyperoxia did not
altered mecanoreflex MSNA activation. In contrast, hyperoxia attenuates
metaboreflex activation. This effect could lead to a diminished activation of
the sympathetic nervous tone in heart failure and have beneficial effects.
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served systolic function in hospital settings: a French observational
cohort survey
Olivier Hanon (1), Francois Dievart (2), Pascal De Groote (3), Annelore
Le Maux (4), George Pisica-Donose (4)
(1) Hôpital Broca, Paris, France – (2) Clinique Villette, Dunkerque,
France – (3) Hôpital cardiologique CHRU, Lille, France – (4) BMS,
Dépt. Médical Cardiovasculaire, Rueil Malmaison, France
Background: Few data are available about real life and management of
patients heart failure with preserved systolic function (HF-PSF).
Objective: To describe patients, disease characteristics and treatment strat-
egies implemented in HF-PSF patients hospitalized for confirmed acute HF
with LVEF≥45%.
Methods: An observational study was conducted in 68 hospital in
France with 2 steps: (1) a registry part in patients hospitalized for confirmed
acute HF for estimation of proportion of HF-PSF patients in the overall HF
patients. (2) a detailed part with data collection of patients recently diagnosed
for HF-PSF (LVEF ≥ 45% evaluated within 8 days following hospitalization
date).
Results: 707 HF patients were enrolled in the registry with a proportion of
51% with HF-PSF. In detailed part 364 HF-PSF patients were selected, with a
mean age of 79 years, 59%female, and a mean BMI 27.7kg/m.
Main cardiovascular characteristics of HF-PSF patients were: atrial fibrilla-
tion (51%), coronary heart disease (32%), peripheral arterial disease (15%)
and stroke (13%) as CV antecedents and hypertension (78%), obesity (45.5%)
and diabetes (29%) as risk factors.
Mean values were: blood pressure 133/86mmHg, HR 92beats/min, creati-
nine 13.8mg/l, haemoglobin 12.0g/dl. BNP was performed in 243 patients with
a median value of 684 pg/ml and Nt-pro-BNP in 77 patients with a median
value of 3999 pg/ml. Mean ejection fraction was 58±8%.
Non CV co-morbidities were: renal failure(39%), COPD(20%), walking
disorders (22%), depression(12%),cognitive disorders(8%)and cancers(5%).
Treatment at discharge included: diur. (85%), ACE-i(57%), βB (56%), Ca
antag (27%), ARB (20%), aldosterone blockers (13%), digoxin (16%), antico-
agulants (52%), statins (48%), aspirin (32%) and amiodarone (28.5%).
Conclusion: Much is not known about the epidemiology and management
of HF-FSP in France but our study try to improve the knowledge on this dis-
ease with real life data even if until today there is no specific treatment.
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Previous studies have shown that thyroid hormone (TH) signaling is altered
after acute myocardial infarction or myocardial hypertrophy with potential
physiological consequences. We investigated whether such changes are related
to the severity of cardiac dysfunction.
Myocardial infarction was induced in rats by coronary artery ligation
(AMI), while SHAM operated animals served as controls (SHAM, n=8). Both
AMI and SHAM hearts were studied after 34 weeks. AMI were divided to
heart failure (AMI-HF, n=6) and non-heart failure group (AMI-NHF, n=7) as
assessed by the ratio of lung weight to body weight (LGW/BW) and right ven-
tricle weight to body weight (RV/BW). Contractile function and left ventric-
ular (LV) remodeling was assessed by echocardiography. TRα1 was increased
in both border and remote regions of viable LV of AMI-NHF (2.0 fold and 1.8
fold), while it decreased in AMI-HF (2.0 fold and 1.5 fold) vs SHAM, p<0.05.
TRβ1 was reduced in border and remote regions in AMI-HF (2.8 fold and 2.0
fold) and AMI-NHF (3.6 fold and 2.0 fold) vs SHAM, p<0.05. T3 and T4
were not different between groups. Accordingly, this response corresponded to
changes in cardiac function (table) and in MHC isoform expression. A marked
increase in β-MHC was observed in both border and remote regions of LV of
AMI-HF (76% and 75%), p<0.05 vs both SHAM and AMI-NHF while a small
but significant increase in β-MHC was found in both border and remote
regions of LV in AMI-NHF (62% and 60%) as compared to SHAM (48% and
50%).
 LGW/BW RV/BW LVEDD (mm)
LVEDS 
(mm) EF%
SHAM 3.77 (0.15) 0.35 (0.02) 6.9 (0.15) 4.0 (0.2) 75.6 (2.3)
AMI-HF 3.95 (0.4) 0.43 (0.02) 8.8 (0.22)* 7.1 (0.3)* 41.2 (2.6)
AMI-NHF 6.90 (0.8)** 0.82 (0.1)** 10.4 (0.50)** 9.2 (0.5)** 27 (2.0)
*p<0.05 vs SHAM, **p<0.05 vs SHAM and AMI-HF 
Post-infarct remodelling results in tissue hypothyroidism. The occurrence of heart 
failure is accompanied by distinct changes in TR and MHC isoform expression 
corresponding to a marked regression to the fetal pattern.
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